Clinical trials: Conduction of Electrocardiogram
Hepatitis B
Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
This study will evaluate the effect of a single dose of bepirovirsen on the QT interval corrected by Fridericia's formula (QTcF) as compared to placebo.
- Trial name
- NCT06422767
- Testing
- Bepirovirsen
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Conduction of Electrocardiogram
Single-Lead ECG Conduction Interval Algorithm
The goal of this prospective, single-center and observational study is to develop and validate an optimization algorithm for single-lead ECG conduction intervals via the wearable ECG patches combined with synchronized heart sound…
- Trial name
- NCT07667465
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Vivalink
Infections, Respiratory Tract
Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers
This is Phase I, 4-period, randomized, active-and placebo-controlled, double-blind crossover, single-dose study to evaluate the effects of a therapeutic (1000 milligram [mg]) and supratherapeutic (1800 mg) dose of GSK2140944 with…
- Trial name
- NCT02257398
- Testing
- GSK2140944, Moxifloxacin
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Human Immunodeficiency Virus
Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction
This study is being conducted to comply with the Food and Drug Administration (FDA) recommendation that all new non anti-arrhythmic drugs be assessed for cardiac repolarization effects through electrocardiographic evaluation.
- Trial name
- NCT02027454
- Testing
- GSK1265744, Moxifloxacin
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Acute Heart Failure (AHF), Cardiac Arrhythmia
Arrhythmia Detection With MEMO Patch Plus in Patients With Acute Heart Failure
This prospective, multicenter, open-label, single-group exploratory clinical trial evaluates the clinical effectiveness of extended electrocardiographic monitoring with MEMO Patch Plus for detecting clinically significant…
- Trial name
- MMPP-HF (NCT07792772)
- Testing
- MEMO Patch Plus
- Where
- 3 sites in South Korea
- Volunteers
- 45 people
- Sponsor
- HUINNO Co., Ltd
HIV Infections
Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin
This study will aim to evaluate the effect of therapeutic and supratherapeutic oral doses of GSK3640254 on cardiac conduction compared to placebo and a single oral dose of Moxifloxacin in healthy adult participants.
- Trial name
- NCT04563845
- Testing
- GSK3640254, Moxifloxacin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Atrial Fibrillation (AF), Arrhythmias Cardiac
Detection and Classification of Cardiac Rhythm and Atrial Fibrillation Using a Finger-worn Ring
Everbeat is a finger-worn ring that has a built-in electrocardiogram (ECG). In this study the investigators ensure that the ECG as read by the everbeat correctly classifies heart rhythms and detects atrial fibrillation.
- Conditions
- Atrial Fibrillation (AF), Arrhythmias Cardiac, Tachycardia, Palpitations
- Trial name
- FINDER-AF (NCT06892938)
- Testing
- Atrial Fibrillation Identification
- Where
- 3 sites in United States
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Everbeat
Hypertrophic Cardiomyopathy, Nonsustained Ventricular Tachycardia
Extended ECG Monitoring in HCM Patients
The purpose of this study is to determine, among a large cohort of 300 consecutive patients with hypertrophic cardiomyopathy, if extended ambulatory monitoring using the iRhythm Technologies, Inc.
- Conditions
- Hypertrophic Cardiomyopathy, Nonsustained Ventricular Tachycardia, Ventricular Tachycardia, Atrial Fibrillation
- Trial name
- EXAMINE-HCM (NCT04056715)
- Testing
- Zio XT
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- iRhythm Technologies, Inc.
Healthy Subjects
Study to Assess Cardiac Conduction of GSK1349572
This will be a randomized, partial-blind, placebo-controlled, single dose, cross-over trial investigating the effect of GSK1349572 on cardiac repolarization as compared to placebo in healthy adult males and females.
- Trial name
- NCT00996021
- Testing
- GSK1349572 250 mg, Moxifloxacin 400 mg
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Fibrillation, Atrial, Atrial Fibrillation
Odiparcil QT Definitive Study
This study is being completed to demonstrate the lack of effect of repeat dosing with Odiparcil on the QTc interval.
- Trial name
- NCT00437242
- Testing
- Odiparcil
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atrial Fibrillation, Premature Atrial and Ventricular Beats
A Study to Determine the Feasibility of Wireless Electrocardiography
The investigators are conducting a prospective, observational study to examine the ECG waveforms captured by the new medical device as compared to a traditional Holter monitor for subsequent use in visual diagnoses of atrial and…
- Conditions
- Atrial Fibrillation, Premature Atrial and Ventricular Beats, Conduction Defects, Normal Sinus Rhythm
- Trial name
- NCT02162394
- Testing
- Observational ambulatory ECG monitoring
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Peerbridge Health, Inc
Infections, Bacterial
A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
This is a randomized, partially-blinded, placebo and moxifloxacin-controlled, single dose, 4-period, balanced crossover study. The primary objective of this study is to separately assess the effects of a therapeutic and…
- Trial name
- NCT01803399
- Testing
- GSK1322322 1200 mg, GSK1322322 3000 mg, Moxifloxacin
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
Approximately 40 healthy subjects will be enrolled. Each subject will participate in the study for approximately 9 weeks. There will be four treatment sequences with a 5-7 day washout between treatments.
- Trial name
- NCT01353729
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline